# US 2016/0243098 A1 · Use of pridopidine to improve cognitive function and for treating alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0243098 A1
- Document ID: US20160243098A1
- Status: Published application
- Kind: A1
- Application number: 15/052,368
- Filed: 2016-02-24
- Published: 2016-08-25
- Earliest claimed: 2015-02-25
- Assignees: Teva Pharmaceuticals International GmbH; Board of Regents, The University of Texas System
- Inventors: Michal Geva; Ilya Bezprozvanny; Merav Bassan; Michael Hayden
- Web page: https://patentgrep.com/patent/US20160243098A1

## CPC

- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 211/24: by sulfur atoms to which a second hetero atom is attached
- C07D 211/42: attached in position 3 or 5
- C07D 211/52: having an aryl radical as the second substituent in position 4
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.

## Claims

### Claim 1

A method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cognitive function is selected from the group consisting of global cognitive functioning, sustained cognition, memory, language, executive functioning, and attention.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cognitive function is memory.

### Claim 4 (depends on 3)

The method of claim 3, wherein memory is short term memory or working memory.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is afflicted with a cognitive deficit.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is prone to or predisposed to have a cognitive deficit.

### Claim 8 (depends on 6)

The method of claim 6, wherein the cognitive deficit is a memory deficit.

### Claim 9 (depends on 8)

The method of claim 8, wherein the memory deficit is a short-term memory deficit or memory loss.

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The method of claim 9 wherein the memory loss is caused by one or more of age-related changes in memory, mild cognitive impairment, dementia or depression.

### Claim 12 (depends on 6)

The method of claim 6, wherein the cognitive deficit is caused by or associated with a disease or disorder.

### Claim 13 (depends on 12)

The method of claim 12, wherein the disease or disorder is a disease or disorder associated with NMDA receptor.

### Claim 14 (depends on 12)

The method of claim 12, wherein the disease or disorder is schizophrenia, epilepsy, an anxiety disorder or Huntington's disease.

### Claim at position 15

15-16. (canceled)

### Claim 17 (depends on 12)

The method of claim 12, Wherein the disease or disorder is selected from the group consisting of major depressive disorder (MDD), Parkinson's disease, Alzheimer's disease, tardive dyskinesia, depression, sickle cell anemia, stroke, chronic pain syndrome, addiction, mild cognitive impairment, memory loss, memory deficit, a memory deficit related to brain injury or a post-stroke event, a learning deficiency, and behavioral and cognitive problems associated with brain tumors, dementia, dementia associated with Lewy Bodies, age-related cognitive decline, psychosis, attention deficit disorder (ADHD), bipolar disorder, brain injury, mood and affective disorders, Tourette's syndrome, mental retardation, progressive supranuclear palsy, Creutzfeldt-Jacob disease, Corticobasal Degeneration, vascular dementia, and Pick's disease.

### Claim at position 17

18-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the amount of pridopidine or a pharmaceutically acceptable salt thereof is administered to the human subject once daily.

### Claim 21 (depends on 1)

The method of claim 1, wherein the amount of pridopidine or a pharmaceutically acceptable salt thereof is administered more often than once daily.

### Claim 22 (depends on 1)

The method of claim 1, wherein the periodic administration continues for at least 3 days, more than 30 days, more than 42 days, 8 weeks or more, at least 12 weeks, at least 24 weeks, more than 24 weeks, or 6 months or more.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the amount of pridopidine administered is about 22.5 mg/day, about 45 mg/day, about 67.5 mg/day, about 90 mg/day, about 100 mg/day, about 112.5 mg/day, about 125 mg/day, about 135 mg/day, about 150 mg/day, about 180 mg/day, about 200 mg/day, about 250 mg/day, or about 315 mg/day.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable salt of pridaoidine is pridopidine hydrochloride.

### Claim at position 25

27-35. (canceled)

### Claim 36

A pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof for use in treating a subject afflicted with a disease or disorder associated with a cognitive deficit.

### Claim at position 27

-46. (canceled)

### Claim 47

A method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.

### Claim at position 29

48-89. (canceled)
